(Total Views: 565)
Posted On: 06/04/2025 10:10:29 PM
Post# of 154570
Quote:
If my memory serves, around 18-22% of Western population won’t receive full benefit, if any, from Leronlimab due to the Delta32 deletion.
In the United States it would be around 9% -10% for single allele and less than 1% for double allele.
(9)
(0)
